Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $6.00 at JMP Securities

Taysha Gene Therapies (NASDAQ:TSHA - Free Report) had its target price lifted by JMP Securities from $5.00 to $6.00 in a research note released on Thursday morning,Benzinga reports. They currently have a market outperform rating on the stock.

A number of other research analysts have also recently commented on TSHA. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research report on Monday, April 28th. Canaccord Genuity Group upped their target price on shares of Taysha Gene Therapies from $8.00 to $9.00 and gave the company a "buy" rating in a research report on Friday, May 16th. Needham & Company LLC reaffirmed a "buy" rating and issued a $6.00 target price on shares of Taysha Gene Therapies in a research report on Thursday, April 10th. Citigroup reaffirmed an "outperform" rating on shares of Taysha Gene Therapies in a research report on Thursday. Finally, Chardan Capital upped their target price on shares of Taysha Gene Therapies from $7.00 to $9.00 and gave the company a "buy" rating in a research report on Thursday. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $7.00.

Taysha Gene Therapies Trading Up 2.0%

Shares of TSHA stock traded up $0.05 on Thursday, hitting $2.76. 1,731,330 shares of the stock traded hands, compared to its average volume of 3,006,702. The firm's 50-day moving average price is $1.92 and its two-hundred day moving average price is $1.90. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.51 and a current ratio of 5.51. The stock has a market capitalization of $593.33 million, a PE ratio of 4.37 and a beta of 0.90. Taysha Gene Therapies has a twelve month low of $1.05 and a twelve month high of $4.32.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last posted its earnings results on Thursday, May 15th. The company reported ($0.08) EPS for the quarter, meeting analysts' consensus estimates of ($0.08). Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. The company had revenue of $2.30 million for the quarter, compared to analysts' expectations of $1.48 million. During the same quarter in the prior year, the company posted ($0.10) earnings per share. As a group, analysts anticipate that Taysha Gene Therapies will post -0.35 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in TSHA. Quantum Private Wealth LLC boosted its stake in shares of Taysha Gene Therapies by 3.6% in the fourth quarter. Quantum Private Wealth LLC now owns 794,976 shares of the company's stock valued at $1,375,000 after purchasing an additional 27,360 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Taysha Gene Therapies by 33.1% during the fourth quarter. Bank of New York Mellon Corp now owns 450,261 shares of the company's stock worth $779,000 after buying an additional 111,989 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Taysha Gene Therapies by 2.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 474,257 shares of the company's stock worth $820,000 after buying an additional 11,390 shares during the period. E Fund Management Co. Ltd. purchased a new stake in shares of Taysha Gene Therapies during the fourth quarter worth approximately $31,000. Finally, Commonwealth Equity Services LLC lifted its stake in Taysha Gene Therapies by 110.4% in the fourth quarter. Commonwealth Equity Services LLC now owns 59,069 shares of the company's stock worth $102,000 after acquiring an additional 31,000 shares during the last quarter. Hedge funds and other institutional investors own 77.70% of the company's stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.